As the specialty care global business unit of Sanofi, they are focused on rare diseases, rare blood disorders, multiple sclerosis, oncology and immunology. More than 30 years since they began, they remain just as committed to and passionate about advancing therapies that offer hope to patients and families.

Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established themselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. In 2018, with the acquisitions of Bioverativ and Ablynx, they further expanded their focus to include rare blood disorders, bringing deep expertise in hematology.